Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Stakeholders from different industries convened to discuss the roadmap ahead to become the next innovation powerhouse at ...

The Crimson spoke to a range of commercial realtors, startup founders, and a commercial lab space owner to understand how the immense draw of Kendall Square has forced the myriad startup companies ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Best-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

India’s CDMO market has seen a record growth trajectory due to cost advantages, technological advancements, and strong ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein ...